CA-VELODYNE-LIDAR,-INC.
Velodyne Lidar, Inc. announces the promotion of Rick Tewell to Chief Operating Officer. Tewell assumes leadership of the company’s vast manufacturing efforts at its Megafactory in San Jose, California. He joined the company in September 2017 as Senior Vice President of Automated Manufacturing and was promoted to Chief Advanced Manufacturing Officer prior to the promotion to COO. He brings a wealth of expertise to the day-to-day production of Velodyne’s industry-leading lidar sensor product line.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005168/en/
According to Marta Hall, Velodyne’s President and Chief Business Development Officer, Velodyne “recruited Rick Tewell to manage Robotics and Advanced Technology, and within a year it was clear he could lead Operations as COO. Velodyne Lidar is at the extreme edge of high tech, and Rick meets the challenge with da Vinci-like multiple talents. In the last three months Rick upgraded the entire Velodyne Megafactory with robotics and newly designed innovative processes for production. As COO he brings a futuristic vision and fresh energy to the operations of the company.”
“My main responsibility,” said Tewell, “is to take a design that came from the mind of a genius, David Hall [Velodyne’s Founder and CEO], and make it into a product worthy of the Velodyne name. I work with David and Anand [Gopalan, Velodyne’s Chief Technology Officer] to translate these wonderful designs that have the ability to change the world into something that is manufacturable and then ramp production to meet the demand. To take an invention from Dave Hall and turn it into a manufacturable product is a huge responsibility and one that I take very seriously. It’s an incredible opportunity. I get out of bed excited to go to work, and I go to bed thinking about it.”
According to Tewell, the job of Chief Operating Officer at Velodyne is unlike any other. Between designing and manufacturing the highest quality sensors on the market comes the equally challenging task of inventing and building the machines that then build the sensors.
“For our sensors to be able to see so far and produce incredibly accurate data for autonomous vehicles to use, we have to employ incredibly precise processes, which include utilizing robotics and automation. So we need to also invent the machines that will build our sensors.” Given the uniqueness of Velodyne’s products, Tewell pointed out that he must address the complex processes of “taking something that’s never been invented or built before and building tens of thousands -- hundreds of thousands -- millions of them. It is a whole series of inventions to produce the sensor invention. So, it is not just the genius of the lidar itself; it’s the genius of saying, ‘This is what you are going to need to invent in order to manufacture the sensor.’”
Before coming to Velodyne, Tewell established a successful career in the automotive semiconductor industry, including stops at Fujitsu and NVIDIA. Rick remembers, “The idea that cars eventually would be robots emerged while Dave Hall was participating in the DARPA Grand Challenge. At NVIDIA we were creating the brains that would be used in self-driving cars.” Tewell’s interest and experience in developing key technologies for autonomous mobility grew over the years. Finally, Tewell decided to join Velodyne with the clear realization that he would be “aligning with a company that will be one of, if not the, principal company in the self-driving industry.”
Tewell recognizes the essential role Velodyne’s products have in enabling safe mobility at scale. “We are working hard to meet the next wave of demand for sensors to put on autonomous vehicles. Scaling up will drive the cost down to where the price is attractive to all customers. But we will never compromise on quality. It is critical from an operations standpoint that our product will ultimately impact someone’s life. This realization needs to permeate every aspect of what we do. This is not a piece of technology that is going to stay in a box. When you put a sensor on a car the person in that car is trusting that technology to keep them safe.”
About Velodyne Lidar
Founded in 1983 and headquartered in Silicon Valley, Velodyne is a technology company known worldwide for its real-time 3D lidar computing and software platforms. The company evolved after founder David Hall invented the HDL-64 Solid-State Hybrid lidar sensor in 2005. Since then, Velodyne Lidar, Inc. emerged as the unmatched market leader of real-time 3D vision systems used in a variety of commercial applications including autonomous vehicles, vehicle safety systems, mobile mapping, aerial mapping, and security. Its products range from the high-performance, surround view Ultra-Puck™ VLP-32, classic HDL-32/64 and cost-effective VLP-16, the new VLS-128, to the upcoming, hidden Velarray™. Velodyne’s rich suite of perception software and algorithms are the key enablers of its perception systems. Velodyne supports customers from offices in San Jose, Detroit, Frankfurt, and Beijing. For more information, visit http://www.velodynelidar.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20181115005168/en/
Contact:
David Cumpston Landis Communications for Velodyne Lidar, Inc. (415) 359-2316 velodyne@landispr.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
